



an Open Access Journal by MDPI

# Vaccination of Patients with Immune-Mediated Diseases

Guest Editors:

submissions:

### Message from the Guest Editors

Prof. Dr. Mikhail Kostik Patients with immune-mediated diseases are at increased risk of developing infections, due to disease-related Prof. Dr. James Galloway immune dysfunction and applying of immunosuppressive drugs. Additional factors of increased infection risk include Dr. Dimitri Poddighe disease activity, malnutrition, surgical interventions, and concomitant chronic diseases, such as obesity, diabetes mellitus, atopic dermatitis, asthma, and others. Biologic Deadline for manuscript therapy with and without immune suppressors can reliably control inflammatory activity in many patients with 20 September 2024 immune-mediated diseases. Infections are the most common complications associated with biological treatment and immune suppressors. Vaccination is a wellknown and effective tool, which allows for reducing the frequency and severity of infectious episodes, and indirectly might reduce the risks of disease flare and failure to achieve remission, and significantly improve disease course and outcomes. This research topic is devoted to theoretical and practical experience of vaccinations of immune mediated pediatric and adult diseases.



mdpi.com/si/162811







an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

### **Contact Us**

*Vaccines* Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/vaccines vaccines@mdpi.com